帕博利珠单抗联合自体细胞因子诱导杀伤细胞一线治疗后，晚期血小板减少性鳞状非小细胞肺癌的快速反应
Rapid Response of Advanced Squamous Non-Small Cell Lung Cancer with Thrombocytopenia after First-Line Treatment with Pembrolizumab Plus Autologous Cytokine-Induced Killer Cells.
作者信息
Hui Zhenzhen, Zhang Xinwei, Ren Baozhu, Li Runmei, Ren Xiubao
机构信息
Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; National Clinical Research Center for Cancer, Tianjin, China; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; National Clinical Research Center for Cancer, Tianjin, China; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China; Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
出版信息
Front Immunol. 2015 Dec 17;6:633. doi: 10.3389/fimmu.2015.00633. eCollection 2015.
We present the first clinical evidence of advanced squamous non-small cell lung cancer with severe thrombocytopenia showing dramatic improvement after first-line treatment with pembrolizumab plus autologous cytokine-induced killer cells.
我们展示了晚期鳞状非小细胞肺癌伴严重血小板减少症经帕博利珠单抗联合自体细胞因子诱导的杀伤细胞一线治疗后显著改善的首个临床证据。
Zotero 插件